AE
Methodology breakdown computing — it will appear here on its own.
AEON Biopharma Inc. - Ordinary Shares - Class A (AEON) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
Computing the full ratio and business-activity breakdown for AEON — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 52.80 | NEUTRAL |
| Stochastic %K (14) | 63.22 | NEUTRAL |
| CCI (20) | 128.58 | SELL |
| Williams %R (14) | -36.78 | NEUTRAL |
| MACD (12,26,9) | 0.01 | BUY |
| ROC (10) | 15.08 | BUY |
| Momentum (10) | 0.04 | BUY |
| EMA (10) | 0.26 | BUY |
| SMA (10) | 0.27 | BUY |
| EMA (20) | 0.26 | BUY |
| SMA (20) | 0.25 | BUY |
| EMA (30) | 0.28 | BUY |
| SMA (30) | 0.26 | BUY |
| EMA (50) | 0.35 | SELL |
| SMA (50) | 0.32 | SELL |
| EMA (100) | 0.51 | SELL |
| SMA (100) | 0.57 | SELL |
| EMA (200) | 0.70 | SELL |
| SMA (200) | 0.80 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Background via Yahoo Finance — informational, not part of the verdict.
🟡 BULLISH LEAN
The main driver: outperforming the market by 8.1%, RSI in healthy zone. More signals pointing up than down. Not full confluence yet, but the weight of evidence is bullish. Use `!alert AEON [level]` to catch the entry, or `!plan AEON` to size small.
Scores: 3 bullish / 1 bearish
No real edge — avoid
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 62 |
| ⏰ 4H | BULLISH | 47 |
| 🕐 1H | BULLISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
